Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Income from Continuing Operations (2018 - 2026)

Immunovant filings provide 8 years of Income from Continuing Operations readings, the most recent being 110635000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations changed 0.44% to 110635000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 464199000.0 through Dec 2025, down 21.29% year-over-year, with the annual reading at 413840000.0 for FY2025, 59.58% down from the prior year.
  • Income from Continuing Operations hit 110635000.0 in Q4 2025 for Immunovant, up from 126502000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 28158000.0 in Q1 2021 and bottomed at 126502000.0 in Q3 2025.
  • Average Income from Continuing Operations over 5 years is 71338700.0, with a median of 61329500.0 recorded in 2022.
  • The largest annual shift saw Income from Continuing Operations grew 18.68% in 2023 before it tumbled 116.11% in 2024.
  • Immunovant's Income from Continuing Operations stood at 41385000.0 in 2021, then plummeted by 52.78% to 63227000.0 in 2022, then rose by 18.68% to 51418000.0 in 2023, then tumbled by 116.11% to 111122000.0 in 2024, then rose by 0.44% to 110635000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Income from Continuing Operations are 110635000.0 (Q4 2025), 126502000.0 (Q3 2025), and 120613000.0 (Q2 2025).